Literature DB >> 15374832

Chronic ventricular myocyte-specific overexpression of angiotensin II type 2 receptor results in intrinsic myocyte contractile dysfunction.

Masaharu Nakayama1, Xinhua Yan, Robert L Price, Thomas K Borg, Kenta Ito, Atsushi Sanbe, Jeffrey Robbins, Beverly H Lorell.   

Abstract

ANG II type 2 receptor (AT(2)) is upregulated in failing hearts, but its effect on myocyte contractile function is not known. We measured fractional cell shortening and intracellular Ca(2+) concentration transients in left ventricular myocytes derived from transgenic mice in which ventricle-specific expression of AT(2) was driven by the myosin light chain 2v promoter. Confocal microscopy studies confirmed upregulation of AT(2) in the ventricular myocytes and partial colocalization of AT(2) with AT(1). Three components of contractile performance were studied. First, baseline measurements (0.5 Hz, 1.5 mmol/l extracellular Ca(2+) concentration, 25 degrees C) and study of contractile reserve at faster pacing rates (1-5 Hz) revealed Ca(2+)-dependent contractile dysfunction in myocytes from AT(2) transgenic mice. Comparison of two transgenic lines suggested a dose-dependent relationship between magnitude of contractile dysfunction and level of AT(2) expression. Second, activity of the Na(+)/H(+) exchanger, a dominant transporter that regulates beat-to-beat intracellular pH, was impaired in the transgenic myocytes. Third, the inotropic response to beta-adrenergic versus ANG II stimulation differed. Both lines showed impaired contractile response to beta-adrenergic stimulation. ANG II elicited an increase in contractility and intracellular Ca(2+) in wild-type myocytes but caused a negative inotropic effect in myocytes from AT(2) transgenic mice. In contrast with beta-adrenergic response, the depressed response to ANG II was related to level of AT(2) overexpression. The depressed response to ANG II was also present in myocytes from young transgenic mice before development of heart failure. Thus chronic overexpression of AT(2) has the potential to cause Ca(2+)- and pH-dependent contractile dysfunction in ventricular myocytes, as well as loss of the inotropic response to ANG II.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374832     DOI: 10.1152/ajpheart.00957.2003

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  11 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Conditional expression of the type 2 angiotensin II receptor in mesenchymal stem cells inhibits neointimal formation after arterial injury.

Authors:  Jian Feng; Jian-Ping Liu; Li Miao; Guo-Xiang He; De Li; Hai-Dong Wang; Tao Jing
Journal:  J Cardiovasc Transl Res       Date:  2014-08-14       Impact factor: 4.132

3.  Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury.

Authors:  Yanfei Qi; Hongwei Li; Vinayak Shenoy; Qiuhong Li; Fong Wong; Ling Zhang; Mohan K Raizada; Colin Sumners; Michael J Katovich
Journal:  Exp Physiol       Date:  2011-10-03       Impact factor: 2.969

4.  Inhibition of DNA methylation in newborns reprograms ischemia-sensitive biomarkers resulting in development of a heart ischemia-sensitive phenotype late in life.

Authors:  Yanyan Zhang; Meizi Yang; Yong Li; Bailin Liu; Lubo Zhang; Daliao Xiao
Journal:  Reprod Toxicol       Date:  2021-09-15       Impact factor: 3.421

5.  Effects of cardiac overexpression of the angiotensin II type 2 receptor on remodeling and dysfunction in mice post-myocardial infarction.

Authors:  Jiang Xu; Ying Sun; Oscar A Carretero; Liping Zhu; Pamela Harding; Edward G Shesely; Xiangguo Dai; Nour-Eddine Rhaleb; Edward Peterson; Xiao-Ping Yang
Journal:  Hypertension       Date:  2014-04-14       Impact factor: 10.190

Review 6.  Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling.

Authors:  Naureen Fatima; Sanket N Patel; Tahir Hussain
Journal:  Hypertension       Date:  2021-04-12       Impact factor: 10.190

Review 7.  Genetically modified mouse models used for studying the role of the AT2 receptor in cardiac hypertrophy and heart failure.

Authors:  Maria D Avila; James P Morgan; Xinhua Yan
Journal:  J Biomed Biotechnol       Date:  2011-04-27

Review 8.  Anti-fibrotic Potential of AT2 Receptor Agonists.

Authors:  Yan Wang; Mark Del Borgo; Huey W Lee; Dhaniel Baraldi; Baydaa Hirmiz; Tracey A Gaspari; Kate M Denton; Marie-Isabel Aguilar; Chrishan S Samuel; Robert E Widdop
Journal:  Front Pharmacol       Date:  2017-08-31       Impact factor: 5.810

9.  Prolonged AT1R activation induces CaV1.2 channel internalization in rat cardiomyocytes.

Authors:  Tamara Hermosilla; Matías Encina; Danna Morales; Cristian Moreno; Carolina Conejeros; Hilda M Alfaro-Valdés; Felipe Lagos-Meza; Felipe Simon; Christophe Altier; Diego Varela
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

10.  Withaferin A attenuates ovarian cancer-induced cardiac cachexia.

Authors:  Natia Q Kelm; Alex R Straughn; Sham S Kakar
Journal:  PLoS One       Date:  2020-07-28       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.